Tacrolimus is an immunosuppressant responsible for inhibiting T-lymphocyte signal transduction as well as interleukin-2 (IL-2) transcription and is one of the most common immunosuppressive drugs administered to kidney transplant recipients (141, 151–154). The gene discussed is IL2; the disease is urogenital neoplasm.